stoxline Quote Chart Rank Option Currency Glossary
  
CytoMed Therapeutics Limited (GDTC)
1.06  -0.01 (-0.93%)    03-13 16:00
Open: 1.01
High: 1.06
Volume: 4,096
  
Pre. Close: 1.07
Low: 1.01
Market Cap: 12(M)
Technical analysis
2026-03-13 4:37:18 PM
Short term     
Mid term     
Targets 6-month :  1.38 1-year :  1.62
Resists First :  1.19 Second :  1.38
Pivot price 1.06
Supports First :  0.99 Second :  0.86
MAs MA(5) :  1.05 MA(20) :  1.05
MA(100) :  1.47 MA(250) :  1.87
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  83.8 D(3) :  83.2
RSI RSI(14): 49.8
52-week High :  3.68 Low :  0.72
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ GDTC ] has closed above bottom band by 48.7%. Bollinger Bands are 89.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.06 - 1.07 1.07 - 1.07
Low: 1 - 1 1 - 1.01
Close: 1.05 - 1.06 1.06 - 1.07
Company Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.

Headline News

Mon, 02 Mar 2026
Interview with the Chairman: CytoMed Therapeutics Ltd. (NASDAQ:GDTC) - The Wall Street Transcript

Fri, 06 Feb 2026
CytoMed Therapeutics And 2 More Penny Stocks With Promising Prospects - simplywall.st

Thu, 05 Feb 2026
CytoMed Therapeutics Strengthens Future with Advanced Therapies - timothysykes.com

Wed, 28 Jan 2026
Cancer cell therapy company hits back at claims about its first human trial - Stock Titan

Wed, 28 Jan 2026
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress - Yahoo Finance

Tue, 13 Jan 2026
Biotech seeks investor views on share-based access to cell therapy - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 12 (M)
Shares Float 4 (M)
Held by Insiders 67.3 (%)
Held by Institutions 0.5 (%)
Shares Short 198 (K)
Shares Short P.Month 27 (K)
Stock Financials
EPS -0.25
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.47
Profit Margin 0 %
Operating Margin -452.2 %
Return on Assets (ttm) -22.9 %
Return on Equity (ttm) -42.4 %
Qtrly Rev. Growth 101 %
Gross Profit (p.s.) 0.05
Sales Per Share 0.06
EBITDA (p.s.) -0.28
Qtrly Earnings Growth 0 %
Operating Cash Flow -3 (M)
Levered Free Cash Flow -2 (M)
Stock Valuations
PE Ratio -4.24
PEG Ratio 0
Price to Book value 2.2
Price to Sales 17.03
Price to Cash Flow -3.95
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android